963 COMPLETE TUMOR ABLATION WITH IODINE 131 RADIOLABELED MONOCLONAL ANTIBODY (Mab) AGAINST HUMAN NEUROBLASTOMA (NB) XENOGRAFTED IN NUDE MICE

The aim of this study was to investigate the therapeutic efficacy of -radioimmunotherapy of ovarian cancer in mice using different fractionated treatment regimens. The study was performed using the monoclonal antibody MX35 F labeled with the -particle emitter .Methods. Nude mice were intraperitoneally inoculated with ~ cells of the cell line NIH:OVCAR-3. Four weeks later 6 groups of animals were given F as a single or as a repeated treatment of up to 6 times ( in each group). The fractionated treatments were given every seventh day. Control animals were treated with unlabeled F (). Eight weeks posttreatment the animals were sacrificed and the presence of macro- and microscopic tumors and ascites was determined.Results. The tumor-free fractions (TFFs) of the animals, defined as the fraction of animals with no macro- and microtumors and no ascites, were 0.17, 0.11, 0.39, 0.44, 0.44, and 0.67 when treated with F once or 2, 3, 4, 5, or 6 times, respectively. Repeated treatment 3 times or more resulted in a significantly higher () TFF than compared to treatment once or twice. The presence of ascites decreased from 15 out of 18 animals in the group given only one treatment to zero for the 2 groups given 5 or 6 fractions. Treatment with unlabeled F resulted in a TFF of zero.Conclusion. Weekly repeated intraperitoneal injections of tolerable amounts of activity of F of up to 6 times produced increased therapeutic efficacy without observed toxicity, indicating a potential increase of the therapeutic index.

Download Full-text

EXPERIMENTAL IMMUNOTHERAPY OF HUMAN MELANOMA WITH HUMAN MONOCLONAL ANTIBODY TO A TUMOR ANTIGEN (OFA-I-2) USING ATHYMIC NUDE MICE

Basic Mechanisms and Clinical Treatment of Tumor Metastasis ◽

10.1016/b978-0-12-695680-1.50034-x ◽

1985 ◽

pp. 511-522

Author(s):

Mitsuo Katano ◽

Reiko F. Irie

Keyword(s):

Monoclonal Antibody ◽

Nude Mice ◽

Tumor Antigen ◽

Human Monoclonal Antibody ◽

Human Melanoma ◽

Athymic Nude Mice

Download Full-text

Clinical application of contrast-enhanced ultrasound after percutaneous renal tumor ablation

British Journal of Radiology ◽

10.1259/bjr.20190183 ◽

2019 ◽

Vol 92 (1103) ◽

pp. 20190183 ◽

Cited By ~ 1

Author(s):

Fang Guo ◽

Bing Hu ◽

Lei Chen ◽

Jia Li

Keyword(s):

Local Recurrence ◽

Tumor Ablation ◽

Renal Tumors ◽

Ablation Zone ◽

Recurrent Tumors ◽

Contrast Enhanced Ct ◽

Contrast Enhanced ◽

Enhanced Ct ◽

Complete Tumor

Objective: To evaluate the effectiveness of contrast-enhanced ultrasound (CEUS) in detecting incomplete ablation and local recurrence of renal tumors after percutaneous radiofrequency ablation (RFA). Methods: 31 patients were included for RFA treatment and underwent CEUS examination after RFA, ablation zone and contrast distribution in the ablation area were observed, CEUS images were compared with enhanced CT/MRI images to determine the residual tumors and local recurrence of renal tumors. Results: The average maximum diameters of the tumor and the ablation zone after the first RFA were 32.3 ± 14.7 mm and 35.9 ± 12.2 mm, respectively. A higher rate of complete tumor ablation was achieved if the ablation zone was larger than the primary tumor (p = 0.026). Within 1 month after RFA, contrast-enhanced CT/MRI examinations demonstrated incomplete ablation in 9 of 31 patients (29.0%), while CEUS revealed incomplete ablation in 8 of 31 patients (25.8%). The sensitivity, specificity, positive predictive value and negative predictive value of CEUS in evaluating complete ablation of renal tumors were 88.9%, 100%, 100%, 95.7%, respectively. During the follow-up period, local recurrence was reported in 2 (7.4%) of the 27 patients with complete tumor ablation. Tumor recurrence signs in the two patients were identified by both CEUS and contrast-enhanced CT/MRI. Therefore, both the sensitivity and specificity of CEUS for the evaluation of tumor recurrence were 100%. Conclusion: After percutaneous RFA of renal tumors, the effectiveness of CEUS in the follow-up assessment of residual and recurrent tumors is basically the same as that of contrast-enhanced CT/MRI. Advances in knowledge: In this study, we evaluated the effectiveness of CEUS in the follow-up assessment of residual and recurrent tumors after RFA is basically the same as that of contrast-enhanced CT/MRI. Combining multiple follow-up methods may improve the detection rate of residual or recurrent tumors.

Download Full-text